Skip to content
BHP

CagriSema (cagrilintide + semaglutide) safety profile & UK regulatory status

Research reference

Reviewed by the BestHealingPeptides Editorial Team ·

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for CagriSema (cagrilintide + semaglutide) as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. CagriSema (cagrilintide + semaglutide) is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

CagriSema is not approved, so there is no UK Summary of Product Characteristics; the figures below come from published trials and company announcements. In REDEFINE 1 (Garvey et al., NEJM 2025), gastrointestinal adverse events affected 79.6% of participants on CagriSema and 39.9% on placebo, mainly transient and mild to moderate. Novo Nordisk reported that these included nausea (55% vs 12.6%), constipation (30.7% vs 11.6%) and vomiting (26.1% vs 4.1%), and that discontinuations due to adverse events were 5.9% with CagriSema versus 3.5% with placebo in REDEFINE 1, and 8.4% versus 3% in REDEFINE 2 (Novo Nordisk, 18 December 2025).

In REDEFINE 2 (adults with type 2 diabetes; Davies et al., NEJM 2025), gastrointestinal adverse events were reported by 72.5% on CagriSema and 34.4% on placebo. In the Phase II trial in type 2 diabetes (Frías et al., Lancet 2023), adverse events were reported by 68% of the CagriSema group, 71% of the semaglutide group and 80% of the cagrilintide group; no level 2 or 3 hypoglycaemia and no fatal adverse events were reported.

The cardiovascular outcomes trial REDEFINE 3 (NCT05669755) is listed on ClinicalTrials.gov as active, not recruiting, with primary completion in 2027. This reference does not state a class warning for CagriSema because none has been issued in an approved label.

Reported contraindications & cautions

  • Not a licensed medicine — there is no UK Summary of Product Characteristics and no formal contraindication list
  • Semaglutide, one component, is licensed separately and has its own UK product information; see the semaglutide entry

Known formulation interactions

  • No approved product information exists for the combination, so no interaction list can be cited. See the semaglutide entry for the licensed component.

UK regulatory status

CagriSema is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction as of 29 October 2026. Novo Nordisk submitted a New Drug Application to the US FDA on 18 December 2025 and said an FDA decision was anticipated by late 2026; the FDA's 2026 novel drug approvals list (current to 20 October 2026) does not include it. This reference found no announced MHRA or EMA submission and makes no prediction about UK availability.

Without a marketing authorisation, CagriSema is not available as a medicine through MHRA-regulated UK channels. Semaglutide is licensed on its own, but the combination with cagrilintide is not. Supply for human use outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012.

CagriSema and its components are not named on the WADA Prohibited List; WADA's S0 category covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use, so athletes should check its status with their anti-doping organisation. Not a controlled drug under the Misuse of Drugs Act 1971. For animal research under ASPA, both component peptides require standard project and personal licences.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. CagriSema (cagrilintide + semaglutide) is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full CagriSema (cagrilintide + semaglutide) research context including mechanism, study citations, and references, see the main CagriSema (cagrilintide + semaglutide) research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.